Combining and intratumoral administration of these engineered oncolytic viruses inhibit primary tumor growth, prevent contralateral untreated tumor growth, generate a vaccine‐like immune response, activate tumor‐specific T cells, and extend the overall survival (OS) rate of the studied mice.[150] Intratumorally administration of oncolytic vaccinia virus (VACV; JX‐594) effectively amplified the frequency of tumor‐specific CD8+ T cells and reduced the infiltration and number of immunosuppressive cells in the TME. Here, CD8A is linked to neoplasm.